On 20.03.2017 BioMaxima SA and Pure Biologics sp. z o.o. signed an agreement for the cooperation in the area of commercialization of R&D results related to in vitro diagnostics. Following technologies developed by Pure Biologics will be employed:
1. A platform for antibodies selection from libraries
2. A platform for modified aptamers selection
3. A technology for obtaining recombinant proteins useful in in vitro diagnostics
BioMaxima and Pure Biologics signed a long-term cooperation agreement which includes the implementation of developed diagnostic tests for detection of cancer or bacterial and viral infections. Pure Biologics will be responsible for the technology development while BioMaxima will take care of validation, prototype construction and market introduction.
 
More information: reuters.com and money.pl